FRIDAY, March 7 (HealthDay News) -- A 300-μg dose of the angiotensin II vaccine CYT006-AngQb can reduce blood pressure in patients with mild to moderate hypertension, according to a report published in the March 8 issue of The Lancet.
Alain C. Tissot, Ph.D., of Cytos Biotechnology AG in Zurich-Schlieren, Switzerland, and colleagues conducted a double-blind, placebo-controlled phase IIa trial of 72 patients with mild to moderate hypertension, of whom 24 were randomized to receive three 100-μg doses of CYT006-AngQb vaccine, while 24 were randomized to receive 300 μg and the remaining 24 were given placebo. The injections were administered at the start of the study and at four and 12 weeks.
There was a mean reduction in daytime ambulatory blood pressure of -9.0/-4.0 mm Hg in the 300-μg group versus placebo, and the treatment also reduced the early morning blood-pressure surge in this group, the researchers report. Although there were five serious events -- two in the 100-μg group, two in the 300-μg group and one in the placebo group -- none appeared to be related to the treatment, while three patients in the 100-μg group and seven in the 300-μg group developed mild flu-like symptoms.
"Later-stage clinical trials will be needed to show efficacy and safety in a broader hypertensive population," the authors write.
Several authors disclosed financial ties to Cytos Biotechnology AG, and the company also provided funding for the study.
Abstract
Full Text (subscription or payment may be required)
